eShowcase: ISI Solutions Platform
Regulatory solution suite from ISI migrates to new platform for improved integration
Regulatory solution suite from ISI migrates to new platform for improved integration
Image Solutions Inc. (Whippany, NJ) has migrated its regulatory product suite for the life sciences industry into the ISI Solutions Platform built on Microsoft's .NET Framework. By moving to the .NET Framework, companies will have one integrated platform from which to manage, review, and publish electronic submissions to the FDA.
The ISI Solutions Platform provides the technology foundation for the company's full suite of products. Its regulatory suite includes its flagship submission products, eCTDXPress and ISIPublisher. These products address the file preparation time in the submissions process. Additional productivity tools and templates are also included in the ISI Solutions Platform.
The .NET Framework gives the suite interoperability with other systems within and outside the company, including document management systems. It also features flexibility, solutions that can be easily scaled to the size of the organization, and common interfaces.
ISI, (973) 560-0404, www.imagesolutions.com
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
